The effect of food on tramadol and celecoxib bioavailability following oral administration of Co-Crystal of Tramadol-Celecoxib (CTC): a randomised, open label, single-dose, crossover study in healthy volunteers

dc.contributor.authorEncina, Gregorio
dc.contributor.authorEncabo, Mercedes
dc.contributor.authorEscriche, Marisol
dc.contributor.authorLahjou, Mounia
dc.contributor.authorSicard, Eric
dc.contributor.authorSmith, Kevin
dc.contributor.authorGascón, Neus
dc.contributor.authorPlata Salamán, Carlos
dc.contributor.authorVidela, Sebastià
dc.date.accessioned2020-11-24T13:25:43Z
dc.date.available2020-11-24T13:25:43Z
dc.date.issued2018
dc.date.updated2020-11-24T13:25:43Z
dc.description.abstractackground and Objective Co-Crystal of Tramadol-Celecoxib (CTC), in development for the treatment of moderate to severe acute pain, is a first-in-class co-crystal containing a 1:1 molecular ratio of two active pharmaceutical ingredients; rac- tramadol·HCl and celecoxib. This randomised, open-label, crossover study compared the bioavailability of both components after CTC administration under fed and fasting conditions. Methods Healthy adults received single doses of 200 mg CTC under both fed and fasting conditions (separated by a 7-day washout). Each dose of CTC was administered orally as two 100 mg tablets, each containing 44 mg tramadol·HCl and 56 mg celecoxib. In the fed condition, a high-fat, high-calorie meal [in line with recommendations by the US Food and Drug Administration (FDA)] was served 30 min before CTC administration. Tramadol, O-desmethyltramadol and celecoxib plasma concentrations were measured pre- and post-dose up to 48 h. Pharmacokinetic parameters were calculated using non-compartmental analysis. Safety was also assessed. Results Thirty-six subjects (18 female/18 male) received one or both doses of CTC; 33 provided evaluable pharmacokinetic data under fed and fasting conditions. For tramadol and O-desmethyltramadol, fed-to-fasting ratios of geometric least-squares means and corresponding 90% confidence interval (CI) values for maximum plasma concentration (Cmax) and extrapolated area under the plasma concentration-time curve to infinity (AUC∞) were within the pre-defined range for comparative bio- availability (80-125%). For celecoxib, Cmax and AUC∞ fed-to-fasting ratios (90% CIs) were outside this range, at 130.91% (116.98-146.49) and 129.34% (121.78-137.38), respectively. The safety profile of CTC was similar in fed and fasting conditions. Conclusions As reported for standard-formulation celecoxib, food increased the bioavailability of celecoxib from single-dose CTC. Food had no effect on tramadol or O-desmethyltramadol bioavailability.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec697976
dc.identifier.issn1173-2563
dc.identifier.pmid30008052
dc.identifier.urihttps://hdl.handle.net/2445/172304
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1007/s40261-018-0672-y
dc.relation.ispartofClinical Drug Investigation, 2018, vol. 38, num. 9, p. 819-827
dc.relation.urihttps://doi.org/10.1007/s40261-018-0672-y
dc.rightscc by-nc (c) Springer Nature, 2018
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject.classificationTractament del dolor
dc.subject.classificationAnalgèsics
dc.subject.classificationOpiacis
dc.subject.otherPain treatment
dc.subject.otherAnalgesics
dc.subject.otherOpioids
dc.titleThe effect of food on tramadol and celecoxib bioavailability following oral administration of Co-Crystal of Tramadol-Celecoxib (CTC): a randomised, open label, single-dose, crossover study in healthy volunteers
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
697976.pdf
Mida:
892.81 KB
Format:
Adobe Portable Document Format